主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
中文
English
Русский
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
NPCE
#2547
Neuropace, Inc. Common Stock
14.580
0
-0.95%
版块:
基础:
利润货币:
日范围
年范围
日变化
-0.95%
每月变动
-9.97%
6个月变化
+37.81%
年变化
+37.81%
前一天收盘价
14.720
0
Open
14.580
0
Bid
Ask
Low
14.580
0
High
14.580
0
交易量
30
市场
股票
医疗保健
NPCE
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
24.47 M
25.1 M
28.34 M
32.56 M
—
Valuation ratios
Enterprise value
227.48 M
29.54 M
259.15 M
350.92 M
1.4 B
Price to earnings ratio
-4.65
-0.75
-7.7
-12.03
-54.54
Price to sales ratio
3.71
0.78
3.86
4.08
15.61
Price to cash flow ratio
-6.81
-0.96
-12.83
-18.16
-79.39
Price to book ratio
2.28
1.02
12.24
40.67
58.01
Enterprise value to EBITDA ratio
-9.82
-0.73
-9.71
-16.52
-72.34
Profitability ratios
Return on assets %
0.27
0.41
0.31
0.29
0.23
Return on equity %
0.49
1.35
1.6
3.39
1.56
Return on invested capital %
1 195.31
1 140.71
494.27
416.78
—
Gross margin %
74
71.38
73.56
73.94
306.88
Operating margin %
52.54
89.62
41.54
27.12
78.39
EBITDA margin %
-51.28
-88.39
-40.8
-26.58
-76.65
Net margin %
79.85
103.43
50.38
33.97
103.27
Liquidity ratios
Quick ratio
13.44
8.02
5.02
4.48
18.64
Current ratio
14.28
8.9
5.71
5.37
22.33
Inventory turnover
1.5
1.49
1.65
1.69
1.52
Asset turnover
0.34
0.37
0.59
0.79
0.92
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
0.37
0.46
0.53
0.63
2.27
Long term debt to total equity ratio
0.68
1.52
2.76
7.43
16.08
Per share metrics
Operating cash flow per share
1.48
1.5
0.76
0.61
0.52
EBIT per share
-1.43
-1.66
-1.05
-0.74
-0.58
EBITDA per share
-1.4
-1.64
-1.03
-0.73
-0.56
Total debt per share
—
—
—
—
—
Cash per share
6.96
3.15
2.57
1.81
7.62
Net current asset value per share
8
3.97
3.59
2.79
11.62
Tangible book value per share
4.43
1.41
0.8
0.28
2.2
Working capital per share
7.44
3.53
2.96
2.27
9.52
Book value per share
4.43
1.41
0.8
0.28
2.2
新闻
LivaNova (LIVN) Tops Q4 Earnings and Revenue Estimates
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
NeuroPace, Inc. (NPCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
Leerink Partners将NeuroPace股票目标价从19美元上调至20美元
NeuroPace stock price target raised to $20 from $19 at Leerink Partners
NeuroPace stock price target raised to $19 from $18 at H.C. Wainwright
NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NeuroPace股价上涨,UBS在强劲第四季度收入后重申买入评级
NeuroPace stock rises as UBS reiterates Buy rating after strong Q4 revenue
NeuroPace公司2025年收入增长25%,预计稳定增长
NeuroPace reports 25% revenue growth for 2025, projects steady growth